Search Results - "Gomez-Roca, C.A."

214eP Exploratory biomarkers evaluation to enhance characterization and explore treatment response prediction in metastatic ovarian cancer patients undergoing therapy with EVT801, a highly selective VEGFR-3 inhibitor.

Authors: Fons, P. Gomez-Roca, C.A. Cassier, P. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS290-S291. 2p.

137P VEGFR-3 expression profiling by histology and mRNA signature to classify patient population for the selective VEGFR-3 inhibitor EVT801.

Authors: Gomez-Roca, C.A. Fons, P. Ancey, P-B. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS235-S236. 2p.

LBA80 Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated/dedifferentiated liposarcomas (WD/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST "Ribociclib/HDM201" basket study.

Authors: Brahmi, M. Tredan, O. Gomez-Roca, C.A. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1266-S1266. 1p.

216eP MegaMOST - A multicenter, open-label, molecularly selected bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort.

Authors: Tredan, O. Saada, E.B. Dalban, C. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS291-S292. 2p.

1558P Mitigating infusion-related reactions (IRRs) with cetirizine and montelukast in patients (pts) receiving REGN7075, an EGFR×CD28 bispecific antibody (bsAb).

Authors: Segal, N.H. Girda, E. Keenan, B.P. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS930-S930. 1p.

1550P Survival outcomes in phase I trial combining the STING agonist ulevostinag ± pembrolizumab in solid tumors (MK1454-001).

Authors: Llop Serna, S. Jimenez Labaig, P. Micheletto, I. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS926-S926. 1p.

984P FIPO23: A first-in-human trial of XON7, a Glyco-Humanized Polyclonal Antibody (GHpAb)targeting multiple tumor antigens in advanced solid tumors.

Authors: Bennouna, J. Shneiker, F. Blay, J-Y. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS643-S643. 1p.

560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment.

Authors: Pedrazzoli, A.B. Azaro Moreno, V. Gomez-Roca, C.A. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS483-S483. 1p.

795TiP A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors.

Authors: Ray-Coquard, I.L. Liu, J.F. O'Malley, D. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS593-S594. 2p.

1925MO Regomune study: A phase II study of regorafenib + avelumab in solid tumors. Results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Authors: Godbert, Y. Cousin, S. Bellera, C. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1120-S1120. 1p.

758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial.

Authors: Saint-Ghislain, M. Abdeddaim, C. Chaltiel, R. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS518-S518. 1p.

557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial.

Authors: Coutzac, C. Bigot, F. Vansteene, D. et al.

Source: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS415-S415. 1p.

1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC).

Authors: Martin Romano, P. Roubaud, G. Lavaud, P. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1334-S1334. 1p.

781TiP AGADIR: A basket multicenter open-label phase II study evaluating the first in class TLR7/8 agonist BDB001 in combination with atezolizumab and stereotactic body radiation therapy in patients with advanced solid tumors.

Authors: Italiano, A. Coutzac Bergouignan, C. Pasquier, D. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS898-S898. 1p.

392P Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas.

Authors: Moreno Garcia, V. Cassier, P.A. Doger de Spéville, B. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS716-S716. 1p.

552P Reasons of screening failure during the 28-day screening period in patients identified for inclusion in phase I trials and their outcome.

Authors: Korakis, I. Darbas, T. Mathevet, F. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS612-S612. 1p.

1116 - Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup.

Authors: Moreno, V. Luke, J. Gelmon, K. et al.

Source: European Urology Supplements. Mar2019, Vol. 18 Issue 1, pe1509-e1510. 2p.

439O - A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors.

Authors: Cassier, P. Eberst, L. Garin, G. et al.

Source: Annals of Oncology. 2019 Supplement 6, Vol. 30, pv159-v159. 1p.